Results 41 to 50 of about 2,519 (184)

Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab

Neurotrauma Reports, 2023
Use of anticoagulants is increasing with the aging of societies. The safe first-line drug is likely to be a direct oral anticoagulant (DOAC), but outcomes of treatment of traumatic brain injury (TBI) with anticoagulants are uncertain.
Eiichi Suehiro, Hideyuki Ishihara, Yohei Kogeichi, Tsunenori Ozawa, Koichi Haraguchi, Masaru Honda, Yumie Honda, Makoto Inaba, Ryusuke Kabeya, Naoaki Kanda, Kenta Koketsu, Nobukuni Murakami, Hidetoshi Nakamoto, Kotaro Oshio, Kuniyasu Saigusa, Takashi Shuto, Shuichi Sugiyama, Kenji Suzuyama, Tsuguaki Terashima, Mitsuharu Tsuura, Mitsutoshi Nakada, Hitoshi Kobata, Toshio Higashi, Nobuyuki Sakai, Michiyasu Suzuki   +24 more
doaj   +1 more source

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy

Medicina, 2022
Background and Objectives: Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) is used to treat acute ischemic stroke. Dabigatran is a reversible thrombin inhibitor approved for stroke prevention in patients with nonvalvular ...
Ilga Kikule, Alise Baborikina, Iveta Haritoncenko, Guntis Karelis   +3 more
doaj   +1 more source

No Benefit for Idarucizumab [PDF]

Deutsches Ärzteblatt international, 2016
The review article by Lange et al. on the management of anticoagulation in the setting of endoscopic interventions provides helpful advice and pointers for routine clinical practice (1). Their assessment clashes with the available evidence in one single issue: idarucizumab has thus far not been shown to offer any benefit in terms of the safe ...
openaire   +2 more sources

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals

Research and Practice in Thrombosis and Haemostasis, 2021
Background Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. Objective Our objective was to assess the safety of idarucizumab among patients who received the drug ...
Jameel Abdulrehman, Sahar Zarabi, Carolyne Elbaz, Kerstin deWit, Yulia Lin, Michelle Sholzberg, Rita Selby   +6 more
doaj   +1 more source

Dabigatran-idarucizumab pharmacokinetics-pharmacodynamics in sheep undergoing cardiopulmonary bypass. [PDF]

Perfusion
BackgroundThe effect of the anticoagulant, dabigatran, and its antagonist, idarucizumab, on coagulation remains poorly quantified. There are few pharmacokinetic-pharmacodynamic data available to describe the interaction in humans or animals undergoing ...
Eaton MP, Nadtochiy SM, Stefanos T, Anderson BJ.   +3 more
europepmc   +2 more sources

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis [PDF]

, 2020
Background Application of idarucizumab and hemodialysis are options to reverse the action of the oral anticoagulant dabigatran in emergency situations.
Lehr, Thorsten, Meibohm, Bernd, Fuhr, Laura Maria, Hanke, Nina   +3 more
core   +2 more sources

Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series

Frontiers in Neurology, 2021
Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran.
Senta Frol, Dimitrios Sagris, Mišo Šabovič, George Ntaios, Janja Pretnar Oblak   +4 more
doaj   +1 more source

PERANAN IDARUCIZUMAB UNTUK MENETRALISIR EFEK ANTIKOAGULAN DABIGATRAN [PDF]

, 2019
Latar Belakang: Dabigatran etexilate (Pradaxa) telah disetujui oleh FDA dan Uni Eropa sebagai antikoagulan untuk mencegah stroke dan emboli sistemik pada pasien dengan atrial fibrilasi non-valvular dan satu atau lebih faktor risiko lain.
Soejitno, Andreas, Putra, Ida Bagus Kusuma   +1 more
core   +1 more source

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures. [PDF]

Transfusion
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Shamiea M, Osnis A, Kashoua A, Avnery O, Itchaki G, Isman S, Tohami T, Jarchowsky-Dolberg O, Ellis M.   +8 more
europepmc   +2 more sources

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report

Journal of Medical Case Reports, 2019
Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous
Toshiyuki Ohtani, Ryosuke Sintoku, Tasuku Yajima, Naoyuki Kaneko   +3 more
doaj   +1 more source